Dive Brief:
A combination of Johnson and Johnson’s multiple myeloma drug Darzalex Faspro and immunotherapy Talvey significantly reduced the risk of disease progression or death in people with the blood cancer, opening the door to a potential label expansion for the latter.
Data show that after two years, Talvey plus Darzalex Faspro, with or without the cancer medication Pomalyst, reduced the risk of death by as much as 53% when compared to the standard regimen in people with relapsed or refractory multiple myeloma. Additionally, the drug regimen reduced the risk of disease progression or death by up to 72%. The results were unveiled Saturday and presented at the European Hematology Association annual meeting, as well as published in The New England Journal of Medicine.
J&J has been aiming to expand its blood cancer portfolio, and the latest results push forth Talvey’s prospects. While the drug is relatively new to its portfolio, J&J sees promise in its future. The company plans to expand its approval labeling in the U.S. and Europe.
Dive Insight:
